We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+0.21%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$73.7M
AUM Growth
-$12.6M
Cap. Flow
-$11.6M
Cap. Flow %
-15.7%
Top 10 Hldgs %
67.93%
Holding
43
New
11
Increased
8
Reduced
12
Closed
12

Top Buys

1
OPTN
OptiNose
OPTN
+$5.64M
2
PTCT icon
PTC Therapeutics
PTCT
+$3.32M
3
DGX icon
Quest Diagnostics
DGX
+$2.41M
4
PRGO icon
Perrigo
PRGO
+$1.56M
5
AERI
Aerie Pharmaceuticals
AERI
+$1.36M

Top Sells

1
ACHC icon
Acadia Healthcare
ACHC
+$3.48M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$3.28M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$2.84M
4
HMSY
HMS Holdings Corp.
HMSY
+$2.82M
5
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$2.5M

Sector Composition

1 Healthcare 92.89%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$6.51B
$9.2M 12.49%
551,558
+196,102
+55% +$3.32M
DGX icon
2
Quest Diagnostics
DGX
$23.3B
$6.26M 8.5%
63,610
+25,390
+66% +$2.41M
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$15.5B
$6.06M 8.22%
44,976
+2,884
+7% +$400K
OPTN
4
DELISTED
OptiNose
OPTN
$5.68M 7.71%
+20,041
New +$5.64M
INSM icon
5
Insmed
INSM
$23.5B
$4.93M 6.7%
158,277
-55,099
-26% -$1.63M
CNC icon
6
Centene
CNC
$32.5B
$4.64M 6.3%
92,022
-47,646
-34% -$2.31M
UNH icon
7
UnitedHealth
UNH
$392B
$4.5M 6.11%
20,406
-4,656
-19% -$987K
BIO icon
8
Bio-Rad Laboratories Class A
BIO
$8.12B
$3.29M 4.47%
13,794
-6,448
-32% -$1.56M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$3.07M 4.17%
213,413
+354
+0.2% +$4.86K
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
$2.41M 3.27%
40,330
+22,355
+124% +$1.36M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.83B
$2.4M 3.26%
43,125
-61,941
-59% -$3.28M
NVTA
12
DELISTED
Invitae Corporation
NVTA
$1.97M 2.67%
216,687
-77,132
-26% -$691K
NBIX icon
13
Neurocrine Biosciences
NBIX
$17.1B
$1.92M 2.61%
24,795
-26,702
-52% -$1.82M
NTRA icon
14
Natera
NTRA
$38.8B
$1.8M 2.44%
199,777
-37,341
-16% -$404K
HRTX icon
15
Heron Therapeutics
HRTX
$89M
$1.79M 2.44%
99,181
+36,219
+58% +$591K
NVRO
16
DELISTED
NEVRO CORP.
NVRO
$1.64M 2.23%
23,785
+11,981
+101% +$958K
PRGO icon
17
Perrigo
PRGO
$1.47B
$1.58M 2.14%
+18,129
New +$1.56M
TEVA icon
18
Teva Pharmaceuticals
TEVA
$37.3B
$1.31M 1.78%
+69,124
New +$1.04M
TCMD icon
19
Tactile Systems Technology
TCMD
$643M
$1.25M 1.69%
43,089
-39,887
-48% -$1.16M
SGYP
20
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.06M 1.45%
477,621
+206,519
+76% +$513K
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$1.06M 1.44%
92,518
-12,710
-12% -$142K
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$11.5B
$957K 1.3%
+10,733
New +$933K
ADMS
23
DELISTED
Adamas Pharmaceuticals
ADMS
$858K 1.16%
+25,311
New +$707K
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$846K 1.15%
+66,095
New +$752K
DRRX
25
DELISTED
DURECT Corp
DRRX
$810K 1.1%
87,820
-1,000
-1% -$11.9K
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Asymmetry Capital Management held 43 positions worth $73.7M, down 15% from $86.2M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Asymmetry Capital Management withdrew a net $11.6M in Q4 2017, closing 12 positions and reducing 12 holdings. Its most notable exit was Acadia Healthcare, an estimated $3.48M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Industrials.

Against the trend, Asymmetry Capital Management opened a new position in OptiNose worth $5.68M.

  • Asymmetry Capital Management's largest Q4 2017 buy was OptiNose: 20,041 shares worth $5.68M.
  • Asymmetry Capital Management added most to PTC Therapeutics in Q4 2017, an estimated $3.32M increase.
  • Asymmetry Capital Management's biggest Q4 2017 reduction was Sarepta Therapeutics, cutting an estimated $3.28M.
  • Asymmetry Capital Management fully exited Acadia Healthcare in Q4 2017, selling an estimated $3.48M.
  • Asymmetry Capital Management's ten largest holdings make up 68% of its $73.7M portfolio in Q4 2017.
  • Asymmetry Capital Management opened 11 new positions and closed 12 in Q4 2017.
  • Asymmetry Capital Management's portfolio value fell 15% quarter-over-quarter to $73.7M.

Based on Asymmetry Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.